Liminatus Pharma, Inc. (LIMN)
Develops antibody drugs to help the immune system fight solid cancers.
$0.10+0.00%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-98.3%
The outlook
LIMN is trading near its 52-week low at $0.10, well below both its 50- and 200-day moving averages. Analyst coverage appears thin or unavailable. The overall sentiment leans heavily bearish, reflecting sustained weakness in the stock's recent price action.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range0% of the way from its 52-week low to high
Market cap
$6.9M
52-wk high
$8.06
52-wk low
$0.10
50-day avg
$0.14
200-day avg
$0.54
Trailing P/E
—